CareDx, Inc (NASDAQ:CDNA) Director Sells $385,880.90 in Stock

CareDx, Inc (NASDAQ:CDNA) Director William A. Hagstrom sold 19,391 shares of the firm’s stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the completion of the transaction, the director now owns 53,979 shares in the company, valued at $1,074,182.10. This represents a 26.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CareDx Stock Down 1.3%

Shares of CDNA opened at $18.59 on Monday. CareDx, Inc has a twelve month low of $13.18 and a twelve month high of $34.84. The stock has a market cap of $1.04 billion, a PE ratio of -6.89 and a beta of 2.18. The business’s 50-day moving average price is $17.50 and its 200-day moving average price is $20.21.

CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. During the same quarter in the prior year, the firm posted ($0.03) EPS. CareDx’s revenue was up 17.6% on a year-over-year basis. Analysts expect that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on CDNA. The Goldman Sachs Group lowered their price target on CareDx from $34.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Stephens reiterated an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. HC Wainwright reiterated a “neutral” rating and issued a $25.00 target price on shares of CareDx in a report on Monday, May 5th. Finally, Wall Street Zen lowered shares of CareDx from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, CareDx has a consensus rating of “Moderate Buy” and an average price target of $30.33.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. grew its position in CareDx by 3.4% during the first quarter. Principal Financial Group Inc. now owns 19,624 shares of the company’s stock worth $348,000 after buying an additional 640 shares in the last quarter. Sei Investments Co. boosted its position in shares of CareDx by 1.7% during the 1st quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock valued at $851,000 after acquiring an additional 816 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in shares of CareDx by 3.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock worth $425,000 after purchasing an additional 900 shares in the last quarter. Thompson Davis & CO. Inc. increased its position in shares of CareDx by 6.3% in the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock worth $344,000 after purchasing an additional 950 shares during the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of CareDx by 6.9% in the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company’s stock worth $365,000 after purchasing an additional 1,109 shares during the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.